Lilly Eli & Co Stock Price, News & Analysis

Vida Ventures applauded Aktis Oncology (Nasdaq: AKTS) on entering the public markets after an IPO that raised $318 million. Vida said it co-led Aktis’ Series A, remained a long‑term investor and was the company’s second‑largest shareholder pre‑IPO, with Helen Kim serving on the Aktis board since 2021. Vida co‑founder Brian Goodman served as Aktis’ founding COO and later CBO. Vida highlighted Aktis’ pipeline led by AKY-1189 (actinium-225, Nectin-4) and AKY-2519 (B7-H3), prior private funding of approximately $346 million, and a strategic collaboration with Eli Lilly that Vida described as a deal valued up to $1.2 billion.

Eli Lilly (NYSE: LLY) reported topline 36-week results from the open-label Phase 3b TOGETHER-PsA trial evaluating concomitant Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity/overweight with ≥1 weight-related condition. The study met its primary endpoint: 31.7% on combination therapy achieved ACR50 plus ≥10% weight loss vs 0.8% on Taltz alone (p<.001). A key secondary showed ACR50 rates of 33.5% vs 20.4% (64% relative increase, p<.05). Safety was consistent with known profiles; common adverse events with the combination included nausea, diarrhea, constipation, and injection site reactions. Detailed 36-week data will be presented and reviewed with regulators.

Lilly (NYSE: LLY) agreed to acquire clinical-stage Ventyx Biosciences for $14.00 per share in an all-cash deal valued at approximately $1.2 billion. The acquisition adds Ventyx's small-molecule pipeline, including class-leading NLRP3 inhibitors aimed at oral treatments for inflammatory-mediated diseases across cardiometabolic, neurodegenerative and inflammatory disorders. The deal carries an approximate 62% premium to Ventyx's 30-day VWAP through Jan. 5, 2026, is not subject to financing, and is expected to close in the first half of 2026 pending shareholder and regulatory approvals.

Eli Lilly (NYSE: LLY) reported topline Phase 3 ATTAIN-MAINTAIN results showing oral orforglipron met the primary and all key secondary endpoints for 52-week weight maintenance versus placebo after prior treatment with Wegovy or Zepbound.

Key figures: participants switching from Wegovy retained their weight loss with an average difference of 0.9 kg; those switching from Zepbound showed an average difference of 5.0 kg at 52 weeks. Safety was consistent with prior studies; GI events were most common. Lilly has submitted an NDA to the FDA and received a Commissioner’s National Priority Voucher.

Eli Lilly and Company (NYSE: LLY) will participate in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for Jan. 12-15, 2025. David A. Ricks, Lilly chair and CEO, will appear in a fireside chat on Tuesday, Jan. 13 at 5:15 p.m. ET.

A live audio webcast will be accessible via the company's Webcasts & Presentations investor page and a replay will be available on the same site for approximately 90 days.

Eli Lilly (NYSE: LLY) reported updated Phase 3 EMBER-3 results for Inluriyo (imlunestrant) in ER+, HER2– advanced breast cancer on Dec 12, 2025.

Key efficacy highlights: as monotherapy in ESR1‑mutated patients, imlunestrant reduced risk of progression or death by 38% (median PFS 5.5 vs 3.8 months; HR=0.62) and showed an 11.4‑month median OS improvement (34.5 vs 23.1 months; HR=0.60) (boundary for significance not met). The imlunestrant + abemaciclib combination achieved median PFS 10.9 months (HR=0.59), a favorable OS trend (HR=0.82), and extended time to chemotherapy by >1 year (27.8 vs 15.5 months). Safety remained consistent with prior reports; OS follow‑up is ongoing.

Eli Lilly (NYSE: LLY) announced positive topline Phase 3 TRIUMPH-4 results for investigational triple agonist retatrutide in adults with obesity and knee osteoarthritis at 68 weeks. At the highest dose (12 mg) retatrutide lowered body weight by up to 28.7% (71.2 lbs) and reduced WOMAC pain by up to 4.5 points (75.8%). The trial tested 9 mg and 12 mg doses; 84.0% of participants had baseline BMI ≥35 kg/m². Secondary findings included substantial proportions achieving ≥25% weight loss (58.6% at 12 mg), a systolic blood pressure reduction of 14.0 mmHg at the highest dose, and improvements in non-HDL cholesterol, triglycerides, and hsCRP.

Common adverse events were gastrointestinal (nausea up to 43.2%) and dysesthesia (up to 20.9%); discontinuations for adverse events were 12.2% (9 mg) and 18.2% (12 mg). Seven additional Phase 3 readouts are expected in 2026.

Eli Lilly (NYSE: LLY) will invest more than $6 billion to build a next-generation active pharmaceutical ingredient (API) manufacturing facility in Greenbrier South, Huntsville, Alabama, announced Dec. 9, 2025. The site will produce small-molecule synthetic and peptide medicines and is slated to manufacture orforglipron, Lilly's oral GLP-1 candidate for obesity, which the company expects to submit to regulators by year-end 2025.

Construction is expected to begin in 2026 with completion targeted in 2032. Lilly estimates the project will create 450 permanent high-value roles and about 3,000 construction jobs (total ~3,450 jobs) and says each dollar invested could generate up to 4x in local economic activity. This is Lilly's ninth U.S. manufacturing site announced since 2020 and the third of four new U.S. sites planned.

Eli Lilly (NYSE: LLY) and Adverum Biotechnologies announced the scheduled expiration and completion of Lilly's tender offer to acquire Adverum. The Offer provided $3.56 cash per share plus one non-tradable CVR per share that can pay up to an aggregate $8.91 upon specified milestone achievement. The Offer expired at 11:59 p.m. ET on Dec 8, 2025, and 16,493,335 shares were validly tendered (approximately 64% of outstanding shares). All offer conditions were satisfied and Lilly accepted for payment those shares; the parties expect to consummate the acquisition on Dec 9, 2025.

Legal and advisory roles were disclosed for both parties.